The price of Watsco, Inc. (NYSE:WSO) went up by $2.61 now trading at $143.69. Their shares witnessed a 8.96% increase from the 52-week low price of $131.88 they recorded on 2018-12-24. Even though it is still -34.28% behind the $192.94 high touched on 2018-04-19. The last few days have been rough for the stock, as its price has decreased by -0.62% during the week. It has also performed poorly over the past three months, as it lost around -6.51% while it has so far retreated around -15.19% during the course of a year. The stock of WSO recorded 3.27% uptrend from the beginning of this year till date. The 12-month potential price target for Watsco, Inc. is set at $155.83. This target means that the stock has an upside potential to increase by 8.45% from the current trading price.
When giving their opinion, around 16.67% of Wall Street analysts, which represents 2 out of 12 rated the stock as a Buy. 9 brokerage firms of the remaining 75% rated the stock as a Hold with 1 analyst rating it as a sell. Overall, the number of aggregate WSO shares held by institutional investors represents 98.3% of total shares. 46 institutions entered new Watsco, Inc. (NYSE:WSO) positions, 166 added to their existing positions in these shares, 182 lowered their positions, and 63 exited their positions entirely.
Watsco, Inc. (WSO) trade volume has increased by 48.89% as around 385,526 shares were sold when compared with its 50-day average volume of traded shares which is 258,930. At the moment, WSO is witnessing a downtrend, as it is trading -1.02% below its 20-day SMA, 0.14% above its 50-day SMA, and -12.01% above its 200-day SMA. The company runs an ROE of roughly 16.1%, with financial analysts predicting that their earnings per share growth will be around 15% per annum for the next five year. This will be compared to the 15.3% increase witnessed over the past five years.
The first technical resistance point for Watsco, Inc. (NYSE:WSO) will likely come at $144.96, marking a 0.88% premium to the current level. The second resistance point is at $146.22, about 1.73% premium to its current market price. On the other hand, inability to breach the immediate hurdles can drag it down to $139.14, the lower end of the range. WSO’s 14-day MACD is -1.28 and this negative figure indicates a downward trading trend. The company’s 14-day RSI (relative strength index) score is 48.04, which shows that its stock has been neutral. The 20-day historical volatility for the stock stands at 29.35 percent, which is high when compared to that of the 50-day’s 28.2 percent.
The shares of AgeX Therapeutics, Inc. (NYSE:AGE) has decreased by -0.7%, and now trading at $4.28 on the Wall Street in the intra-day deal, with their shares traded now around 131,279. This is a rise of 45,269 shares over the average 86,010 shares that were traded daily over the last three months.
AGE stock hasn’t performed well over the past 30 days, as it lost -4.25% while its price climbed by 43.14% year-to-date (YTD). Looking at the last few days, it has been tough for the stock, as it tumbled -6.35% over the last week. The stock’s 12-month potential target price is now at $0. This means that the stock price might likely increase by -100% from its current trading price.
AgeX Therapeutics, Inc. (NYSE:AGE) has been utilizing an ROE that is roughly 0%, with stock analysts predicting that the company’s EPS for the next five years will go down by 0% per year, following the 0% drop that was witnessed during the past five years. The stock at the moment is on a downtrend, trading -1.77% below its 20-day SMA, 8.37% above its 50-day SMA, and 7.63% above its 200-day SMA. In percentage terms, the aggregate AgeX Therapeutics, Inc. shares held by institutional investors is 17.3%. 50 institutions jumped in to acquire AgeX Therapeutics, Inc. (AGE) fresh stake, 50 added to their current holdings in these shares, 0 lowered their positions, and 0 left no stake in the company.
The stock’s 9-day MACD is -0.21 and this negative figure indicates a downward trading trend. The company’s 9-day RSI score is 48.24, which shows that its stock has been neutral. The 20-day historical volatility for the shares stand at 102.81 percent, which is less when compared to that of the 50-day’s 116.75 percent. On the daily chart, we see that the stock could reach the first level of resistance at $4.53, sporting a 5.52% premium to the current level. The next resistance point is at $4.78, representing nearly 10.46% premium to the current market price of AgeX Therapeutics, Inc. (AGE). On the other hand, failure to breach the immediate hurdles can drag it down to $3.88, the lower end of the range.